First Phase III results for AstraZeneca and
Daiichi Sankyo’s TROP2-directed antibody drug conjugate
demonstrated statistically significant improvement in
progression-free survival vs. standard chemotherapy in
previously treated locally advanced or metastatic disease
Trial will continue to assess the dual
primary endpoint of overall survival
Positive high-level results from the TROPION-Lung01 Phase III
trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a
statistically significant improvement for the dual primary endpoint
of progression-free survival (PFS) compared to docetaxel, the
current standard of care chemotherapy, in patients with locally
advanced or metastatic non-small cell lung cancer (NSCLC) treated
with at least one prior therapy.
For the dual primary endpoint of overall survival (OS), the data
were not mature and an early trend was observed in favor of
datopotamab deruxtecan versus docetaxel that did not meet the
prespecified threshold for statistical significance at this interim
analysis. The trial will continue as planned to assess OS with
greater maturity. The investigators and participants will remain
blinded to the results.
The safety profile of datopotamab deruxtecan was consistent with
previous clinical trials with no new safety signals identified. All
grade interstitial lung disease was generally consistent with prior
clinical trials, with the majority being low grade. Some Grade 5
events were observed.
Datopotamab deruxtecan is a specifically engineered
TROP2-directed DXd antibody drug conjugate (ADC) being jointly
developed by AstraZeneca and Daiichi Sankyo.
Susan Galbraith, Executive Vice President, Oncology R&D,
AstraZeneca, said: “With TROPION-Lung01, we met the dual primary
endpoint of progression-free survival, challenging the entrenched
standard of care in a previously treated and unselected patient
population that has long deserved an alternative to chemotherapy.
These first Phase III trial results from the datopotamab deruxtecan
clinical program provide compelling evidence for the potential role
this TROP2-directed antibody drug conjugate can play in treating
patients with lung cancer.”
Ken Takeshita, MD, Global Head, Oncology R&D, Daiichi
Sankyo, said: “We are encouraged by the statistically significant
results of the dual primary endpoint of progression-free survival
seen with datopotamab deruxtecan and look forward to the final
overall survival analysis. We plan to share these data with
regulatory authorities to discuss next steps.”
More than one million people worldwide are diagnosed with
advanced NSCLC each year.1,2 While immunotherapy and targeted
therapies have improved outcomes in the 1st-line metastatic
setting, most patients eventually experience disease progression
and receive chemotherapy.3-5 For decades, chemotherapy has been the
last treatment available for patients with advanced NSCLC in the
absence of other treatment options and despite limited
effectiveness and known side effects.3-5 TROP2 is a protein highly
expressed in a large majority of lung cancers. There are currently
no TROP2-directed ADCs approved for the treatment of patients with
lung cancer.6-8
TROPION-Lung01 enrolled patients with and without actionable
genomic alterations, such as EGFR and ALK. Patients with actionable
genomic alterations were previously treated with platinum-based
chemotherapy and an approved targeted therapy. Patients without
actionable genomic alterations were previously treated,
concurrently or sequentially, with platinum-based chemotherapy and
a PD-1 or PD-L1 inhibitor.
The data will be presented at a forthcoming medical meeting and
shared with health authorities.
Notes
Non-small cell lung cancer More than one million people
worldwide are diagnosed with advanced NSCLC each year.1,2 While
immunotherapy and targeted therapies have improved outcomes in the
1st-line metastatic setting, most patients eventually experience
disease progression and receive chemotherapy.3-5 For decades,
chemotherapy has been the last treatment available for patients
with advanced NSCLC in the absence of other treatment options and
despite limited effectiveness and known side effects.3-5
TROP2 is a protein highly expressed in a large majority of lung
cancers.6 There are currently no TROP2-directed ADCs approved for
the treatment of patients with lung cancer.7,8
TROPION-Lung01 TROPION-Lung01 is a global, randomized,
multicenter, open-label Phase III trial evaluating the efficacy and
safety of datopotamab deruxtecan (6.0 mg/kg) versus docetaxel (75
mg/m2) in patients with locally advanced or metastatic NSCLC, with
or without actionable genomic alterations, treated with at least
one prior therapy. Patients without actionable genomic alterations
were previously treated, concurrently or sequentially, with
platinum-based chemotherapy and a prior PD-1 or PD-L1 inhibitor.
Patients with actionable genomic alterations were previously
treated with platinum-based chemotherapy and targeted therapy as
approved for their detected genomic alteration.
The dual primary endpoints of TROPION-Lung01 are PFS as assessed
by blinded independent central review (BICR) and OS. Key secondary
endpoints include investigator-assessed PFS, objective response
rate, duration of response, time to response and disease control
rate as assessed by both BICR and investigator, and safety.
TROPION-Lung01 enrolled approximately 600 patients at sites in
Asia, Europe, North America and South America. For more information
visit ClinicalTrials.gov.
Datopotamab deruxtecan (Dato-DXd) Datopotamab deruxtecan
(Dato-DXd) is an investigational TROP2-directed ADC. Designed using
Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab
deruxtecan is one of five lead ADCs in the oncology pipeline of
Daiichi Sankyo, and one of the most advanced programs in
AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is
comprised of a humanized anti-TROP2 IgG1 monoclonal antibody,
developed in collaboration with Sapporo Medical University,
attached to a number of topoisomerase I inhibitor payloads, an
exatecan derivative, via tetrapeptide-based cleavable linkers.
A comprehensive development program is underway globally with
more than 12 trials evaluating the efficacy and safety of
datopotamab deruxtecan across multiple TROP2-targetable tumors,
including NSCLC, triple-negative breast cancer and hormone
receptor-positive, HER2-low or negative breast cancer. Beyond the
TROPION program, datopotamab deruxtecan is also being evaluated in
novel combinations in several ongoing trials.
In NSCLC, the TROPION-Lung07, TROPION-Lung08 and AVANZAR Phase
III trials are evaluating datopotamab deruxtecan and immune
checkpoint inhibitor combinations as potential 1st-line treatment
options for patients with advanced or metastatic disease, a
strategy informed by the results of two early trials. AstraZeneca
is also researching a potential diagnostic test to help identify
patients most likely to benefit from treatment with datopotamab
deruxtecan.
AstraZeneca and Daiichi Sankyo collaboration AstraZeneca
and Daiichi Sankyo entered into a global collaboration to jointly
develop and commercialize fam-trastuzumab deruxtecan-nxki in March
2019 and datopotamab deruxtecan in July 2020, except in Japan where
Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi
Sankyo is responsible for the manufacturing and supply of
fam-trastuzumab deruxtecan-nxki and datopotamab deruxtecan.
AstraZeneca in lung cancer AstraZeneca is working to
bring patients with lung cancer closer to cure through the
detection and treatment of early-stage disease, while also pushing
the boundaries of science to improve outcomes in the resistant and
advanced settings. By defining new therapeutic targets and
investigating innovative approaches, the Company aims to match
medicines to the patients who can benefit most.
The Company’s comprehensive portfolio includes leading lung
cancer medicines and the next wave of innovations, including
osimertinib and gefitinib; durvalumab and tremelimumab;
fam-trastuzumab deruxtecan-nxki and datopotamab deruxtecan in
collaboration with Daiichi Sankyo; savolitinib in collaboration
with HUTCHMED; as well as a pipeline of potential new medicines and
combinations across diverse mechanisms of action.
AstraZeneca is a founding member of the Lung Ambition Alliance,
a global coalition working to accelerate innovation and deliver
meaningful improvements for people with lung cancer, including and
beyond treatment.
AstraZeneca in oncology AstraZeneca is leading a
revolution in oncology with the ambition to provide cures for
cancer in every form, following the science to understand cancer
and all its complexities to discover, develop and deliver
life-changing medicines to patients.
The Company’s focus is on some of the most challenging cancers.
It is through persistent innovation that AstraZeneca has built one
of the most diverse portfolios and pipelines in the industry, with
the potential to catalyze changes in the practice of medicine and
transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day,
eliminate cancer as a cause of death.
AstraZeneca AstraZeneca is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialization of prescription medicines in
Oncology, Rare Diseases and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries, and its innovative medicines are used by millions of
patients worldwide. For more information, please visit
www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.
References
- Siegel R, et al. Cancer Statistics, 2021. CA Cancer J Clin.
2021;71:7-33.
- World Health Organization. International Agency for Research on
Cancer. Lung Fact Sheet. Available at:
https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf.
Accessed May 2023.
- Chen R, et al. Emerging therapeutic agents for advanced
non-small cell lung cancer. J Hematol Oncol. 2020;13(1):58.
- Majeed U, et al. Targeted therapy in advanced non-small cell
lung cancer: current advances and future trends. J Hematol Oncol.
2021;14(1):108.
- Pircher, A, et al. Docetaxel in the Treatment of Non-small Cell
Lung Cancer (NSCLC) – An Observational Study Focusing on Symptom
Improvement. Anticancer Research. 2013;33(9):3831-3836.
- Mito R, et al. Clinical impact of TROP2 in non‐small lung
cancers and its correlation with abnormal p53 nuclear accumulation.
Pathol Int. 2020;70(5):287-294.
- Rodríguez-Abreau D et al. Pemetrexed plus platinum with or
without pembrolizumab in patients with previously untreated
metastatic nonsquamous NSCLC: protocol-specified final analysis
from KEYNOTE-189. Ann Onc. 2021 Jul;32(7): 881-895.
- American Cancer Society. Targeted Drug Therapy for Non-Small
Cell Lung Cancer. Available at:
https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/targeted-therapies.html.
Accessed May 2023.
US-77561 Last Updated 07/23
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230703436165/en/
Media Inquiries Brendan McEvoy +1 302 885 2677 Chelsea
Ford +1 302 885 2677
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024